Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)

Conditions

• Traumatic Intracranial Hemorrhage

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Repeat Thromboelastography with Platelet Mapping — DIAGNOSTIC_TEST
  Thromboelastography (TEG) is an assay used by many medical professionals to assess coagulopathy, predict outcomes, and guide treatment. Although TEG does not assess platelet function very well, a TEG with platelet mapping (TEG-PM) assay assesses platelet functioning by measuring the percent of arachidonic acid (AA) and adenosine diphosphate (ADP) that are inhibited in the patient's blood.

Study Details

The aim of this study is to see if administering platelets (cells in our blood that stop or prevent bleeding) results in improved platelet function and slows/stops the progression of a head bleed for patients who have a traumatic head bleed and are on antiplatelet therapy (medications that stop blood cells from forming a blood clot) prior to admission.

Key Dates

Start date

Dec 1, 2023

Status verified

Oct 2025

Primary completion

Dec 31, 2026

Completion

Nov 30, 2027

Study Design

Enrollment

225 participants (estimated)

Arms

• Arm: Repeat TEG-PM
  Will receive a repeat TEG-PM after platelet transfusion based on inclusion criteria.
• Arm: No Repeat TEG-PM
  Not eligible to be consented; will proceed with normal course of treatment.

Primary Outcome Measure

Repeat TEG [ Time Frame: 1 hour after platelets given ]

Locations (1)

Find similar trials in Lancaster, PA